study compared LNCaP cells exposed to Enzalutamide for short-term treatment vs. Enzalutamide-resistant and RD-162 (a second-generation AR-antagonist)-resistant LNCaP cells at the single-cell level to better understand the dynamics of treatment resistance in PCa patients (105). Here, AR is linked to posterior cortical atrophy.